FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *	2. Issuer Name **and** Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
McIntosh David M	REXAHN PHARMACEUTICALS, INC. [RNN]	__X__ Director _____ 10% Owner ____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455	3. Date of Earliest Transaction (Month/Day/Year) 06/11/2013	
(Street) ROCKVILLE, MD 20850	4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person
(City) (State) (Zip)	**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**	

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock								2,800	I	By son
Common Stock								2,800	I	By daughter

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(*e.g.*, puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (right-to-buy)	$ 0.5	06/11/2013		A		60,000		(1)	06/11/2023	Common Stock	60,000	$ 0	60,000	D	
Stock Options (right-to-buy)	$ 0.38							(2)	06/18/2022	Common Stock	20,000		20,000	D	
Stock Options (right-to-buy)	$ 1.25							06/06/2012	06/06/2021	Common Stock	20,000		20,000	D	
Stock Options (right-to-buy)	$ 1.17							06/14/2011	06/14/2020	Common Stock	20,000		20,000	D	
Stock Options (right-to-buy)	$ 1.28							06/01/2010	06/19/2019	Common Stock	20,000		20,000	D	
Stock Options (right-to-buy)	$ 3.24							06/30/2009	06/30/2018	Common Stock	20,000		20,000	D	
Stock Options (right-to-buy)	$ 1.4							06/11/2008	06/11/2017	Common Stock	20,000		20,000	D	
Stock															

Options (right-to-buy)	$ 1.2							05/01/2007	05/01/2016	Common Stock	20,000		20,000	D	
Stock Options (right-to-buy)	$ 3							09/12/2006	09/12/2015	Common Stock	20,000		20,000	D	
Stock Options (right-to-buy)	$ 0.8							04/20/2007	04/20/2014	Common Stock	125,000		125,000	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
McIntosh David M C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD 20850	X			

Signatures

/s/ Tae Heum Jeong, as attorney-in-fact for David M. McIntosh		06/13/2013
**Signature of Reporting Person		Date

Explanation of Responses:

***** If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

****** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) These options vest and become exercisable in full on June 11, 2014

(2) These options vest and become exercisable in full on June 18, 2013

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.